PRIVATE AND CONFIDENTIAL November 26, 2018 OLAREGEN THERAPEUTIX INC.Binding Letter of Intent • December 3rd, 2018 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
This letter agreement sets forth our agreement and understanding as to the essential terms of the sale to Generex Biotechnology Corporation (or an affiliate thereof) (the “Purchaser”) by Olaregen Therapeutix Inc. (the “Company”) of equity securities in the capital of the Company equal to fifty-one percent (51%) of the issued and outstanding equity securities in the capital of the Company on a post-closing basis (the “Transaction”). The parties intend this letter agreement to be binding and enforceable, and that it will inure to the benefit of the parties and their respective successors and assigns.
